Development initiatives of HPAPIs and cytotoxic drugs are generally very demanding, both in terms of experience and capital investment. Most companies generally lack the necessary resources to meet the aforementioned requirements and are unable to set up dedicated HPAPI and cytotoxic drug manufacturing facilities. This has led to an increased demand for contract manufacturing service providers in this field.
To order this 300+ page report, which features 75+ figures and 150+ tables, please visit this – https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html
The USD 25 billion (by 2030) financial opportunity within the HPAPI and cytotoxic drugs contract manufacturing market has been analyzed across the following segments:
- Type of Product
- HPAPIs
- Highly Potent Finished Dosage Forms
- Company Size
- Small-sized
- Mid-sized
- Large / Very Large
- Scale of Operation
- Preclinical / Clinical
- Commercial
- Type of Pharmacological Molecule
- Small Molecules
- Biologics
- Type of Highly Potent Finished Dosage Form
- Injectables
- Oral Solids
- Creams
- Others
- Key geographical regions
- North America
- Europe
- Asia Pacific
- Rest of the World
The “HPAPI and Cytotoxic Drugs Manufacturing (3rd Edition) 2020-2030” report features the following companies, which we identified to be key players in this domain:
- AbbVie Contract Manufacturing
- CARBOGEN AMCIS
- Catalent
- Evonik
- Formosa Laboratories
- Intas
- Lonza
- MabPlex
- Pfizer CentreOne
Table of Contents
- Preface
2. Executive Summary
- Introduction
- Market Landscape
- Company Competitive Analysis
- HPAPI and Cytotoxic Drugs Contract Manufacturers based in North America: Company Profiles
- HPAPI and Cytotoxic Drugs Contract Manufacturers based in Europe: Company Profiles
- HPAPI and Cytotoxic Drugs Contract Manufacturers based in Asia Pacific: Company Profiles
- Partnerships and Collaborations
- Recent Expansions
- Capacity Analysis
- Market Sizing and Opportunity Analysis
- Case-In-Point: Contract Manufacturing of Antibody Drug Conjugates
- Concluding Remarks
- Executive Insights
- Appendix 1: Tabulated Data
- Appendix 2: List of Companies and Organizations
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html
About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis Private Limited
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnson@rootsanalysis.com
Facebook – https://www.facebook.com/RootsAnalysis
LinkedIn – https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter – https://twitter.com/RootsAnalysis
Medium – https://medium.com/@RootsAnalysis
Pinterest – https://in.pinterest.com/RootsanalysisPin/_saved/
Quora – https://rootsanalysisinsights.quora.com/
